Expanding Therapeutic Access: Lupin Launches Rivaroxaban Oral Suspension In US Market

Lupin Ltd has announced the launch of Rivaroxaban for oral suspension in the United States, marking a strategic addition to its cardiovascular and anticoagulant portfolio. The product, a generic equivalent of Xarelto oral suspension, is used to reduce the risk of blood clots and stroke in pediatric patients and adults with specific cardiovascular conditions.

Key Highlights From The Product Launch

- Rivaroxaban oral suspension is indicated for use in pediatric patients aged 2 to 11 years for venous thromboembolism (VTE) treatment and prevention  
- The formulation offers an alternative to tablets, improving compliance among children and patients with swallowing difficulties  
- Lupin’s launch follows approval from the US Food and Drug Administration (USFDA), reinforcing its capabilities in complex generics  
- The product will be manufactured at Lupin’s facility in Goa, which has a strong track record of regulatory compliance and global supply  
- Market analysts estimate annual sales of the reference product in the US to be approximately USD 50 million, presenting a meaningful opportunity for Lupin

Portfolio Expansion And Strategic Context

- The launch strengthens Lupin’s presence in the US cardiovascular segment, where it already markets several anticoagulant and antihypertensive therapies  
- It reflects the company’s focus on differentiated dosage forms and pediatric-friendly formulations  
- Lupin continues to invest in R&D for niche generics and specialty products, with a pipeline targeting respiratory, neurology, and oncology segments  
- The company is also expanding its footprint in Europe and Latin America through strategic filings and partnerships

Commercial Outlook

- Distribution has commenced across major US pharmacy chains and hospital networks  
- Lupin expects the launch to contribute to its US revenue growth in H2 FY26, with further pediatric formulations under development

Sources: Bombay Stock Exchange Filings, Lupin Ltd Corporate Announcements, Economic Times Pharma Desk, Business Standard Healthcare Tracker, Reuters USFDA Updates